Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Margolin

Showing results (291-300 of 406) with videos related to

Pageof 41
Sort By:
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Surgical Endoscopy|March 11, 2014
Current status: new technologies for the treatment of patients with fecal incontinenceAndreas M Kaiser, Guy R Orangio, Massarat Zutshi, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaM J Hawkins, M B Atkins, J P Dutcher, et al.
Cancer Treatment Reviews|June 1, 1989
Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanomaM Sznol, J P Dutcher, M B Atkins, et al.
Cancer|September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trialG Somlo, J H Doroshow, A Lev-Ran, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Cancer|September 25, 2014
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933Sylvia M Lee, James Moon, Bruce G Redman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Pageof 41

Showing results (291-300 of 406) with videos related to

Sort By:
Pageof 41
Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.
Surgical Endoscopy|March 11, 2014
Current status: new technologies for the treatment of patients with fecal incontinenceAndreas M Kaiser, Guy R Orangio, Massarat Zutshi, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|January 1, 1994
A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaM J Hawkins, M B Atkins, J P Dutcher, et al.
Cancer Treatment Reviews|June 1, 1989
Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanomaM Sznol, J P Dutcher, M B Atkins, et al.
Cancer|September 16, 2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group studyMichael B Atkins, Jeffrey A Sosman, Sanjiv Agarwala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1990
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cellsM H Bar, M Sznol, M B Atkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1995
Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trialG Somlo, J H Doroshow, A Lev-Ran, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Cancer|September 25, 2014
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933Sylvia M Lee, James Moon, Bruce G Redman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1992
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaG R Weiss, K A Margolin, F R Aronson, et al.
Pageof 41